ProStrakan has a number of exciting products and product opportunities for which we require motivated and like-minded partners to help us realise their global potential.  We would welcome enquiries from interested parties on the opportunities outlined below:

Sancuso
Sancuso is currently in European registration and was launched into the US market in November 2008. ProStrakan has already forged a number of key partnerships for Sancuso and remains interested to find partners in India and Central and Eastern Europe. 

Rectogesic
Rectogesic is being successfully commercialised by ProStrakan and its existing partners in many global markets.  We are looking for potential partners that can register and commercialise Rectogesic in the USA, Japan and Asian territories.

Tostran/Fortesta
We are looking for potential partners that can register and commercialise Tostran/Fortesta in Japan, Asia, CEE/CIS, the Middle East, Australia and New Zealand.

Estradiol Glucoside
ProStrakan owns global rights to the Estradiol Glucoside (E2G) program.  E2G is a conjugated estradiol in Phase II clinical development that offers a unique, patent-protected alternative to current hormone replacement therapies.    

For more information please contact:

Dr Wayne Bowler
VP Business Development

busdev@prostrakan.com
+44 (0)1896 664000